| abstract |
Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarker can be laminin γ2 monomer, PIVKA-II, AFP, CEA, CA19-9, or a combination thereof. Also disclosed herein is the diagnosis, prediction of hepatocellular or pancreatic cancer, classification of risk of hepatocellular or pancreatic cancer by detecting the levels of laminin γ2 monomer, PIVKA-II, AFP, CEA, CA19-9 or a combination thereof. Methods of monitoring the progression of hepatocellular carcinoma or pancreatic cancer. |